| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 60,635 | 49,762 | ||
| General and administrative | 10,799 | 10,936 | ||
| Total operating expenses | 71,434 | 60,698 | ||
| Operating loss | -71,434 | -60,698 | ||
| Interest expense | 3,198 | 2,037 | ||
| Other income, net | 4,053 | 6,779 | ||
| Loss before income tax | -70,579 | -55,956 | ||
| Income tax expense | 115 | 95 | ||
| Net loss | -70,694 | -56,051 | ||
| Of which net loss attributable to noncontrolling interests shareholders | - | -831 | ||
| Of which net loss attributable to controlling interests shareholders | -69,729 | -55,220 | ||
| Basic net loss per share attributable to controlling interest shareholders (usd per share) | - | -0.87 | ||
| Diluted net loss per share attributable to controlling interest shareholders (usd per share) | - | -0.87 | ||
| Weighted-average number of class a ordinary shares, basic (in shares) | - | 63,282,728 | ||
| Weighted-average number of class a ordinary shares, diluted (in shares) | - | 63,282,728 | ||
| Basic net loss per share attributable to controlling interest shareholders (usd per share) | -1.1 | - | ||
| Diluted net loss per share attributable to controlling interest shareholders (usd per share) | -1.1 | - | ||
| Weighted-average number of class a ordinary shares, basic (in shares) | 63,369,984 | - | ||
| Weighted-average number of class a ordinary shares, diluted (in shares) | 63,369,984 | - | ||
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)